Front & Back Matter.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 1, doi. 10.1159/000525192
- Publication type:
- Article
Works matching IS 00093157 AND DT 2022 AND VI 67 AND IP 2
Results: 8
1
2
KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 81, doi. 10.1159/000521751
- By:
- Publication type:
- Article
3
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 67, doi. 10.1159/000521452
- By:
- Publication type:
- Article
4
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 91, doi. 10.1159/000521229
- By:
- Publication type:
- Article
5
Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 96, doi. 10.1159/000521113
- By:
- Publication type:
- Article
6
Synthesis and Antimicrobial Evaluation of Amino Acid Naphthoquinone Derivatives as Potential Antibacterial Agents.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 102, doi. 10.1159/000521098
- By:
- Publication type:
- Article
7
miR-142-3p Regulates Tumor Cell Autophagy and Promotes Colon Cancer Progression by Targeting TP53INP2.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 57, doi. 10.1159/000520750
- By:
- Publication type:
- Article
8
miR-466 Contributes to the Enhanced Antitumor Effect of Bortezomib on Non-Small-Cell Lung Cancer by Inhibiting CCND1.
- Published in:
- Chemotherapy (0009-3157), 2022, v. 67, n. 2, p. 110, doi. 10.1159/000518936
- By:
- Publication type:
- Article